The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial report of a randomized trial of post-prostatectomy prostate cancer radiotherapy using either fluciclovine (18F) or PSMA (68Ga) PET/CT for target dose-escalation.
 
Ashesh Jani
No Relationships to Disclose
 
Vishal Dhere
No Relationships to Disclose
 
Subir Goyal
No Relationships to Disclose
 
Eduard Schreibmann
No Relationships to Disclose
 
Pretesh Patel
No Relationships to Disclose
 
Bruce Hershatter
No Relationships to Disclose
 
Joseph Shelton
No Relationships to Disclose
 
Sheela Hanasoge
No Relationships to Disclose
 
Nikhil Sebastian
No Relationships to Disclose
 
Sagar Patel
No Relationships to Disclose
 
Raghuveer Halkar
No Relationships to Disclose
 
Bridget Fielder
No Relationships to Disclose
 
Olayinka Abiodun-Ojo
No Relationships to Disclose
 
Ismaheel Lawal
No Relationships to Disclose
 
Aliza Mushtaq
No Relationships to Disclose
 
Viraj Master
Honoraria - Ethicon; Exelixis
Research Funding - Exelixis; Merck (Inst)
 
Shreyas Joshi
No Relationships to Disclose
 
Omer Kucuk
No Relationships to Disclose
 
Mehmet Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
David Schuster
Consulting or Advisory Role - Global Medical Solutions Taiwan; Progenics Pharmaceuticals, Inc; Heidelberg University; DuChemBio Co. Ltd.; Telix Pharmaceuticals Limited.
Research Funding - Blue Earth Diagnostics, Ltd; Blue Earth Therapeutics, Ltd; Nihon MediPhysics Co, Ltd.; Telix Pharmaceuticals (US) Inc.; Advanced Accelerator Applications; Xencor; Amgen Inc.
Patents, Royalties, Other Intellectual Property - Inventor(s): Miller, Matthew (Oxford, GB), Gauden, David (Oxford, GB), Schuster, David (Atlanta, GA), Fanti, Stefano (Bologna, IT), Nanni, Cristina (Bologna, IT), Zanoni, Lucia (Bologna, IT), Willoch, Frode (Oslo, NO), Bogsrud, Trond Velde (Oslo, NO), Bac
Other Relationship - PrecisCa; School of Breast Oncology